Electromed, Inc. (NYSE:ELMD) Director Sells $1,385,502.30 in Stock

Electromed, Inc. (NYSE:ELMD) Director Andrew Summers sold 50,751 shares of Electromed stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the transaction, the director now directly owns 65,714 shares of the company’s stock, valued at approximately $1,793,992.20. The trade was a 43.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Andrew Summers also recently made the following trade(s):

• On Thursday, February 20th, Andrew Summers sold 35,273 shares of Electromed stock. The stock was sold at an average price of $28.83, for a total transaction of $1,016,920.59.
• On Wednesday, December 4th, Andrew Summers sold 12,731 shares of Electromed stock. The shares were sold at an average price of $29.98, for a total transaction of $381,675.38.
• On Monday, December 2nd, Andrew Summers sold 17,463 shares of Electromed stock. The stock was sold at an average price of $30.09, for a total value of $525,461.67.

Electromed Trading Up 2.6 %

Shares of ELMD stock opened at $27.46 on Thursday. The firm has a market capitalization of $234.98 million, a price-to-earnings ratio of 36.61 and a beta of 0.33. The firm’s 50 day moving average is $31.36 and its 200-day moving average is $25.59. Electromed, Inc. has a 1 year low of $13.74 and a 1 year high of $35.56.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. B. Riley assumed coverage on Electromed in a research note on Thursday, February 20th. They issued a “buy” rating and a $38.00 price objective on the stock. StockNews.com cut Electromed from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership raised its position in shares of Electromed by 261.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock worth $3,386,000 after acquiring an additional 82,839 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Electromed in the fourth quarter worth about $1,760,000. Sowell Financial Services LLC bought a new stake in Electromed during the 4th quarter worth about $1,518,000. Lazard Asset Management LLC lifted its position in Electromed by 19,860.8% during the 4th quarter. Lazard Asset Management LLC now owns 47,906 shares of the company’s stock valued at $1,415,000 after purchasing an additional 47,666 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Electromed in the 4th quarter valued at about $1,255,000. Institutional investors and hedge funds own 40.82% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.